PCVX · Vaxcyte, Inc.
$58.04
+2.54 (+4.58%)
At close · Jul 21
Market Cap
$8.38B
Shares
144.40M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$766.63M
-65.2%
FY2025
Diluted EPS
-$5.63
-48.2%
FY2025
Operating Cash Flow
-$655.58M
-44.8%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $958.95M | $794.31M | $476.64M | $332.34M | $169.45M | $78.41M | $73.56M | |
| $129.78M | $129.37M | $92.9M | $60.7M | $39.81M | $25.26M | $16.02M | |
| — | $16.4M | $7M | $3.16M | $2.58M | $1.8M | $1.41M | |
| $1.09B | $923.68M | $569.55M | $468.04M | $232.26M | $103.67M | $89.58M | |
| -$1.09B | -$923.68M | -$569.55M | -$468.04M | -$232.26M | -$103.67M | -$89.58M | |
| — | — | $0 | $0 | $2000 | $7000 | $7000 | |
| $113.39M | $119.72M | $109.99M | $62.91M | $8.36M | $344K | $244K | |
| $142.2M | $157.05M | $105.62M | $65.78M | $8.77M | $3.59M | $364K | |
| $0 | $0 | — | — | — | — | — | |
| -$946.53M | -$766.63M | -$463.93M | -$402.27M | -$223.49M | -$100.08M | -$89.22M | |
| -$953.04M | -$761.17M | -$467.98M | -$401.73M | -$223.61M | -$100.32M | — | |
| USD/shares | — | -$5.63 | -$3.80 | -$4.14 | -$3.44 | — | — |
| USD/shares | — | -$5.63 | -$3.80 | -$4.14 | -$3.44 | — | — |
| shares | — | 136.09M | 122M | 97.16M | 64.88M | 51.92M | 29.55M |
| shares | — | 136.09M | 122M | 97.16M | 64.88M | 51.92M | 29.55M |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.68×
EV/EBIT
—
Biotechnology median 26.45×
P/E (TTM)
—
Biotechnology median 7.21×
Key facts
CIK
1649094
CUSIP
92243G108
13F (30d)
24 filings
23 filers
Visit website
Investor relations